Skip to main content
Ascelia Pharma logo

Ascelia Pharma — Investor Relations & Filings

Ticker · ACE ISIN · SE0010573113 LEI · 5493002YR9VCJJPWYN08 ST Manufacturing
Open in API
Filings indexed 295 across all filing types
Latest filing 2024-09-30 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ACE

About Ascelia Pharma

https://www.ascelia.com/

Ascelia Pharma is a biotechnology company focused on developing and commercializing novel drugs for orphan oncology. The company aims to address unmet medical needs for patients with rare cancer conditions. Its lead product candidate, Orviglance, is an oral manganese-based contrast agent for magnetic resonance imaging (MRI). It is designed to improve the detection and visualization of liver metastases, particularly in adult patients with severely impaired kidney function for whom existing contrast agents may be contraindicated. The company's strategy involves identifying, developing, and commercializing innovative treatments for niche cancer-related conditions.

Recent filings

Filing Released Lang Actions
Change in Number of Shares and Votes in Ascelia Pharma AB
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the total number of shares and votes in Ascelia Pharma AB following a rights issue. This type of disclosure regarding capital structure changes, specifically the issuance of new shares, falls under the category of Share Issue/Capital Change.
2024-09-30 English
Major Shareholding Notification 2024
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder ('Avanza Bank Holding AB för Försäkringsaktiebolaget Avanza Pension'). It explicitly lists the 'Reason for major shareholding notification' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' share quantities and resulting percentages. This structure is characteristic of a Major Shareholding Notification, which reports when an investor crosses a specific threshold (here, 5%). This aligns directly with the definition for Major Shareholding Notification (MRQ). The document length is short (3599 chars), but the content is the notification itself, not an announcement of a separate report.
2024-09-25 English
Ascelia Pharma Resolves on a Directed Issue of Convertibles of SEK 7.5 Million
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a 'directed issue of convertibles' by Ascelia Pharma. This constitutes a capital structure change and financing activity. While it mentions an attachment, the document itself provides the full details of the transaction, including the nominal amount, conversion price, interest rates, and the rationale for the board's decision, making it a primary announcement of a capital event rather than just a report publication notice. Therefore, it is classified as a Capital/Financing Update.
2024-09-13 English
Ascelia Pharma beslutar om en riktad emission av konvertibler om 7,5 MSEK
Capital/Financing Update Classification · 100% confidence The document is a press release announcing a specific corporate action: a directed issue of convertible bonds (7.5 MSEK). It details the terms of the conversion, the rationale for the board's decision, and includes standard legal disclaimers regarding securities offerings. While it discusses capital structure, it is a formal announcement of a specific transaction rather than a comprehensive capital update report. According to the 'Menu vs Meal' rule, since this is a press release announcing a corporate action and includes a link to an attached PDF, it is classified as a Report Publication Announcement (RPA).
2024-09-13 Swedish
Ascelia Pharma offentliggör slutligt utfall i fulltecknad företrädesemission om 105 MSEK
Capital/Financing Update Classification · 98% confidence The document is a press release (indicated by "PRESSMEDDELANDE") dated September 5, 2024, announcing the final outcome of a rights issue ("företrädesemission") that raised approximately 105 MSEK. It details the subscription rates, the resulting increase in share capital, and future steps regarding warrants (TO 1) and convertible notes. This type of announcement, focusing on fundraising, capital structure changes, and the final result of a financing round, directly aligns with the definition of a Capital/Financing Update. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER), as it focuses purely on the financing transaction's conclusion, not operational performance or comprehensive financial statements. It is a specific announcement about capital raising, making 'CAP' the most appropriate classification.
2024-09-05 Swedish
Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Rights Issue
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release titled "Ascelia Pharma Announces Final Outcome in Fully Subscribed SEK 105 Million Rights Issue." It details the subscription results, capital structure changes (increase in shares and share capital), warrant exercise details, and the use of proceeds from a recent financing activity (Rights Issue). This content directly relates to fundraising, capital structure changes, and the issuance of new securities (units, shares, warrants). This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific corporate financing event.
2024-09-05 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.